Login to Your Account

NewCo News

G-Zero Cedes to Start-up G1 in Small-Molecule Inhibitors

By Marie Powers
Staff Writer

Friday, November 16, 2012
Based on discoveries licensed from the University of North Carolina at Chapel Hill, privately held G1 Therapeutics Inc. is trained on the discovery and development of small molecules targeting proteins associated with cell proliferation and growth – specifically, in cancer therapy and biodefense.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription